BI Asset Management Fondsmaeglerselskab A S Purchases New Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO)

BI Asset Management Fondsmaeglerselskab A S bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 1,641 shares of the medical research company's stock, valued at approximately $539,000.

A number of other large investors have also added to or reduced their stakes in the business. Metis Global Partners LLC grew its position in shares of Bio-Rad Laboratories by 4.4% in the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock valued at $234,000 after buying an additional 30 shares during the last quarter. Signaturefd LLC boosted its holdings in Bio-Rad Laboratories by 13.2% in the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock valued at $87,000 after acquiring an additional 31 shares during the last quarter. UMB Bank n.a. raised its holdings in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Bio-Rad Laboratories by 0.7% in the 4th quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock worth $1,488,000 after purchasing an additional 32 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. increased its position in shares of Bio-Rad Laboratories by 3.9% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after buying an additional 34 shares during the period. Institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Up 0.6 %

Shares of BIO traded up $1.46 during trading hours on Wednesday, hitting $243.78. The stock had a trading volume of 307,075 shares, compared to its average volume of 314,965. Bio-Rad Laboratories, Inc. has a 1-year low of $215.38 and a 1-year high of $387.99. The firm has a market capitalization of $6.83 billion, a P/E ratio of -3.75 and a beta of 1.12. The firm has a 50 day simple moving average of $248.55 and a 200-day simple moving average of $306.55. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.48 and a quick ratio of 4.85.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. Sell-side analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BIO shares. StockNews.com downgraded Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Monday, February 17th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Finally, Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $380.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.